Allarity Therapeutics Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives
24 juil. 2023 06h00 HE
|
Allarity Therapeutics, Inc.
New appointments bring therapeutic development expertise and proven leadership to support continued progress of Allarity’s multiple oncology clinical programs BOSTON (July 24, 2023) — Allarity...
Allarity Therapeutics, Inc. Announces Pricing of $11 Million Public Offering
06 juil. 2023 06h00 HE
|
Allarity Therapeutics, Inc.
BOSTON, MA (July 6, 2023) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with...
Initial Data from Allarity’s Phase 2 Trial of IXEMPRA® Indicate Potential for Improved Clinical Benefit in DRP®-Selected Metastatic Breast Cancer Patients
05 juil. 2023 09h45 HE
|
Allarity Therapeutics, Inc.
Boston, MA (July 5, 2023) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (Nasdaq: ALLR), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with...
Allarity Therapeutics Announces Reverse Stock Split of Common Stock
28 juin 2023 11h55 HE
|
Allarity Therapeutics, Inc.
- Common Stock Will Begin Trading on a Post-Split Adjusted Basis on June 29, 2023 Press ReleaseBOSTON, MA (June 28, 2023) – Allarity Therapeutics, Inc. (NASDAQ: ALLR) (“Allarity” or the “Company”),...
Allarity Therapeutics Announces Clarification of Effective Date for Reverse Stock Split
27 juin 2023 18h16 HE
|
Allarity Therapeutics, Inc.
Press Release BOSTON, MA (June 27, 2023) – Allarity Therapeutics, Inc. (NASDAQ: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics...
Allarity Therapeutics Announces Adjournment of Special Meeting of Stockholders
20 juin 2023 16h05 HE
|
Allarity Therapeutics, Inc.
Meeting adjourned to Friday, June 23, 2023 at 1:00 p.m. Eastern Time Press release BOSTON, MA (June 20, 2023) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a...
First Prospective Clinical Validation of Allarity's DRP® Companion Diagnostic to be Presented at 2023 ASCO Annual Meeting
30 mai 2023 06h00 HE
|
Allarity Therapeutics, Inc.
Phase 2 study evaluating the utility of a DRP® companion diagnostic for cisplatin supports its ability to predict drug response in certain breast cancer patients Boston, MA (May 30, 2023) —...
Allarity Therapeutics, Inc. Announces Pricing of $7.5 Million Public Offering
19 avr. 2023 09h18 HE
|
Allarity Therapeutics, Inc.
Allarity Therapeutics, Inc. Announces Pricing of $7.5 Million Public Offering BOSTON, MA (April 19, 2023) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a...
Abstract Evaluating Allarity’s DRP® Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting
11 avr. 2023 07h00 HE
|
Allarity Therapeutics, Inc.
FOR IMMEDIATE RELEASE Abstract Evaluating Allarity’s DRP® Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting Poster presentation focused on a Phase 2 Clinical Study...
Allarity Therapeutics Provides Updates for IXEMPRA and Stenoparib Phase 2 Monotherapy Clinical Studies
28 mars 2023 06h00 HE
|
Allarity Therapeutics, Inc.
Efforts underway to accelerate patient recruitment and amend protocols to improve patient outcomes. Interim data readouts for both studies anticipated in H2 2023. Press release BOSTON — March 28,...